NorthStar, Point Biopharma ink Ac-225 supply deal

By staff writers

September 8, 2021 -- NorthStar Medical Radioisotopes and Point Biopharma Global have signed a supply agreement covering the development and commercialization of the medical radioisotope actinium-225 (Ac-225).

Under the deal, NorthStar will provide its electron accelerator-produced Ac-225 to Point. Point will use the radioisotope in the investigational studies of PNT2001, a prostate-specific membrane antigen (PSMA) for nonmetastatic castrate-sensitive prostate cancer and PNT2004, a fibroblast activation protein-α candidate with potential pan-cancer applications.

Also, Ac-225 will be used to advance Point's new tumor microenvironment tumor-targeting platform.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking